FDA Approves Tecentriq (atezolizumab) for Urothelial Carcinoma

May 18, 2016 -- The U.S. Food and Drug Administration today approved Tecentriq (atezolizumab) to treat the most common type of bladder cancer, called urothelial carcinoma. This is the first product in its class (PD-1/PD-L1 inhibitors) approved to...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news